(INNF)
ULOCUPLUMAB(INNS)
ULOCUPLUMAB(INND)
ULOKUPLUMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENS CXCR4 (CHEMOKINE (C-X-C MOTIF) RECEPTOR 4, FUSIN, STROMAL CELL-DERIVED FACTOR 1 RECEPTOR, SDF-1 RECEPTOR, CXCL12 RECEPTOR, CD184)], HUMAN MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN (1-451) [HOMO SAPIENS VH (IGHV3-48*02 (96.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126- 223), HINGE S10>P (233) (224-235), CH2 (236-345), CH3 (346-450), CHS K2>DEL (451)) (126-451)], (139-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HOMO SAPIENS (V-KAPPA (IGKV1D-16*01 (98.90%) - IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; DIMER (231- 231":234-234")-BISDISULFIDE, RECOMMENDED INN: LIST 72(WHO)
ULOCUPLUMABUM(INN)